Sobi(TM) announces commercial launch of Elocta® in first countries in Europe


Swedish Orphan Biovitrum AB (publ) (Sobi(TM)) today announced the commercial launch of Elocta® (efmoroctocog alfa) in first countries in Europe. Elocta is a recombinant human factor VIII Fc fusion protein with an extended half-life, and is the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.

Elocta is indicated for both prophylaxis and on-demand treatment of bleeding in people with haemophilia A and can be used for all age groups. The SmPC recommended prophylactic dose of Elocta is 50 IU/kg every three to five days. The dose may be personalised by the treating physician in the range of 25 to 65 IU/kg depending on the severity of the factor VIII deficiency, the location and frequency of bleeding, and the patient's activity level and clinical condition.

"The launch of Elocta is an important milestone for the haemophilia community, offering people with haemophilia A in the EU a treatment option that provides extended protection against bleeds", said Geoffrey McDonough, CEO and President at Sobi. "Since the approval of Elocta in the EU, our focus has been to ensure timely and sustainable access to Elocta for people living with haemophilia A. We are delighted to be able to announce that Elocta is now available."

Elocta is a fully recombinant fusion protein produced from a human cell line without the addition of human- or animal-derived protein. The European Commission's approval of Elocta was based on data from the pivotal phase 3 A-LONG clinical study which demonstrated the efficacy, safety and pharmacokinetics of Elocta in previously treated males 12 years of age and older with severe haemophilia A, and from the phase 3 Kids A-LONG clinical study, which demonstrated the efficacy and safety of Elocta in previously treated boys under 12 years of age with haemophilia A.

"Low annualised bleeding rates, comparable with those seen in the pivotal A-LONG and Kids A-LONG trials, have been observed during the ongoing open label, long term follow-up ASPIRE study, with most participants receiving prophylactic treatment with similar weekly Elocta consumption as in the pivotal phase 3 studies", said Birgitte Volck, Senior Vice President, Chief Medical Officer at Sobi. "For long term prophylaxis Elocta offers a dosing regimen that can be personalised to meet the needs of each individual patient."

Sobi and Biogen are collaboration partners in the development and commercialisation of Elocta for haemophilia A, which is also known as Eloctate® (Antihemophilic Factor (Recombinant), Fc Fusion Protein) in Australia, Canada, Japan, New Zealand and the U.S., where it is approved for the treatment of haemophilia A. Sobi holds final development and commercialisation rights in pre-specified territories, which include Europe, North Africa, Russia and certain countries in the Middle East. Biogen leads development and manufacturing of the product and holds commercialisation rights in North America and all other regions in the world outside of the Sobi territory.

- - -

About Elocta®
Elocta (efmoroctocog alfa) is the first recombinant clotting factor VIII therapy in the EU that offers an extended half-life in the body. It is indicated for the treatment and prophylaxis of bleeding episodes in patients with haemophilia A (factor VIII deficiency) and can be used by people of all ages. Elocta was developed by fusing B-domain deleted factor VIII to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body). This enables Elocta to utilise a naturally occurring pathway to prolong the time the therapy remains in the body. While Fc fusion technology has been used in other therapies for more than 15 years, Sobi and Biogen are the first companies to utilise it in the treatment of haemophilia. As with any infused protein, allergic type hypersensitivity reactions and development of inhibitors may occur following administration of Elocta. For full prescribing information visit

About Haemophilia A
Haemophilia A is a rare, chronic, genetic disorder in which the ability of a person's blood to clot is impaired due to missing or reduced levels of a protein known as factor VIII. People with haemophilia A experience bleeding episodes that may cause pain, irreversible joint damage and life-threatening haemorrhages. According to the World Federation of Hemophilia, an estimated 140,000 people worldwide are identified as living with haemophilia A.[1]

Therapies for haemophilia A, the most common form of haemophilia, can be administered either on a schedule to help prevent or reduce bleeding episodes (prophylaxis) or to control bleeding when it occurs (on-demand). The World Federation of Hemophilia recommends that prophylaxis be the goal of therapy because it may prevent bleeding and joint destruction. As a result, regular prophylactic treatment may slow progression of joint disease and may improve quality of life.

About Sobi(TM)
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at

For more information please contact

Media relations  Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of Investor Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135


[1] World Federation of Hemophilia. Annual Global Survey 2012. Accessed July 2015.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Globenewswire





Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer20.3.2018 12:00Pressmeddelande

UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d'Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of excellence located in Barcelona, Spain, today announced a strategic research collaboration to develop novel agents for therapeutic applications. The collaboration will combine Merus' proprietary Biclonics® technology platform and VHIO's expertise in clinical, translational and preclinical research. Josep Tabernero, M.D., Ph.D., M.Sc., Director of VHIO, has served as a scientific advisor to Merus for the past six years. "VHIO is an internationally renowned leader in cancer research. This new collaboration builds on the successful working relationship established in the Phase 1/2 study for MCLA-128, a Biclonics® targeting HER3 signaling, and in the preclinical evaluation of MCLA-158, a Biclonics® target

NIH/NCI Grants Awarded to Inspirata and Case Western Reserve University Projects to Investigate Whole Slide Image Analysis to Predict the Aggressiveness of Certain Cancers20.3.2018 11:13Pressmeddelande

Multiple academic/industry grants and other funding totaling nearly $10M are being used to develop and validate digital pathology image-based risk predictors for breast, lung and head/neck cancers. If validated, the predictors will help identify which patients have a greater probability of cancer recurrence and a greater need for chemotherapy. Vancouver, BC, March 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that it has been awarded a new National Institute of Health/National Cancer Institute (NIH/NCI) R01 grant with its academic partner, Case Western Reserve University (CWRU) in Cleveland, Ohio. This grant will enable the multidisciplinary team of cancer researchers and physicians to develop and validate an image-based risk predictor of aggressiveness in head & neck cancers based on digitized H&E stained pathology images alone. This 5-year $3.15M Academic Industry Partnership (AIP) R01 grant is in add

Auth0 Announces Key Distribution Partnership with AppXite20.3.2018 10:00Pressmeddelande

End-to-end identity management now available to all AppXite resellers LONDON, March 20, 2018 (GLOBE NEWSWIRE) -- Auth0, a global leader in Identity-as-a-Service (IDaaS), has announced a new partnership with AppXite, a global leader in SaaS solutions aggregation and fully owned subsidiary of Atea. Auth0's identity and access management platform will be added to AppXite's SaaS offering, adding even more value to its global reseller offering. Auth0's Universal Identity platform will now be accessible to AppXite's extensive global network of managed service providers (MSPs), value-added resellers (VARs), and systems integrators (SIs) around the world. AppXite's reseller network can integrate Auth0's identity platform into their own offering to increase profitability, expand market share, and help their customers thrive in today's cloud economy. "Over the past few years, we have noticed a marked increase in demand for identity management. Companies are realizing the complexity of trying to

McDonald's Becomes the First Restaurant Company to Set Approved Science Based Target to Reduce Greenhouse Gas Emissions20.3.2018 09:03Pressmeddelande

Company Expected to Prevent 150 Million Metric Tons of Emissions by 2030 OAK BROOK, Ill., March 20, 2018 (GLOBE NEWSWIRE) -- Today, McDonald's announces it will partner with franchisees and suppliers to reduce greenhouse gas emissions related to McDonald's restaurants and offices by 36% by 2030 from a 2015 base year in a new strategy to address global climate change. Additionally, McDonald's commits to a 31% reduction in emissions intensity (per metric ton of food and packaging) across its supply chain by 2030 from 2015 levels. This combined target has been approved by the Science Based Targets initiative(SBTi). Through these actions, McDonald's expects to prevent 150 million metric tons of greenhouse gas emissions from being released into the atmosphere by 2030. This is the equivalent of taking 32 million passenger cars off the road for an entire year or planting 3.8 billion trees and growing them for 10 years. The target will enable McDonald's to grow as a business without growing it

Momentum Group acquires Reklamproffsen in Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) has acquired 70 percent of the shares in Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen is a leading reseller of promotional products, including workwear and profile clothing, in Örebro and the surrounding area. Reklamproffsen generates annual revenue of approximately MSEK 35 with favourable profitability and has 12 employees. Reklamproffsen is one of Örebro's largest resellers of workwear and profile clothing, with a high level of expertise in customising company products. Reklamproffsen has a professional store and showroom in Örebro. Its customers mainly comprise industrial and service companies, and a significant portion of its sales are conducted via customised online stores. "Thanks to its strong customer and supplier relationships and highly skilled employees, Reklamproffsen has achieved successful growth since it was formed in 2000. It is now a well-established company in Örebro and the surrounding area. We anticipate good opportuniti

Momentum Group förvärvar Reklamproffsen i Örebro20.3.2018 08:45Pressmeddelande

Momentum Group AB (publ) har förvärvat 70 procent av aktierna i Reklamproffsen Skandinavien AB ("Reklamproffsen"). Reklamproffsen är en ledande återförsäljare av produktmedia innefattande yrkeskläder och profilkläder i Örebro med omnejd. Reklamproffsen omsätter cirka 35 MSEK per år med god lönsamhet och har 12 anställda. Reklamproffsen är en av Örebros största återförsäljare inom yrkeskläder och profilkläder med hög kompetens inom företagsprofilering. Reklamproffsen har en yrkesbutik och utställning i Örebro. Kunderna utgörs främst av industri- och serviceföretag och en betydande andel av försäljningen sker via kundunika webbshoppar. - Reklamproffsen har med sina starka kund- och leverantörsrelationer och medarbetare med hög kompetens utvecklats framgångsrikt ända sedan starten år 2000. Bolaget är idag ett väletablerat företag i Örebro med omnejd. Vi ser mycket goda möjligheter till vidare utveckling och tillväxt för Reklamproffsen som en del av Momentum Group, säger Ulf Lilius, VD & K

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum